Aibit Investment 'Mecox Curemed' Successfully Secures Additional Strain for Anticancer Substance Production

[Asia Economy Reporter Lim Jeong-su] AIbit announced on the 29th that Mekox Cure Med, a new drug development bio company in which it has invested, has succeeded in additionally securing strains for the production of the anticancer substance Tubulysin.

An AIbit official explained, "We have started full-scale new drug development business through investment in Mekox Cure Med on the 13th," adding, "The speed of anticancer drug development will accelerate through this additional strain acquisition."

According to AIbit, a mass production system for Tubulysin is necessary to accelerate the development speed of the anticancer drug M001, which Mekox Cure Med is developing using Tubulysin. Last year, Mekox Cure Med succeeded in isolating the strain MEHO 001 that produces Tubulysin from domestic soil. This time, they additionally secured MEHO 002, a strain related to MEHO 001.

A Mekox Cure Med official stated, "MEHO 002 has shown a much higher efficiency in producing Tubulysin compared to the existing MEHO 001," evaluating it as "a revolutionary turning point for the development of mass production processes." He added, "We have completed the registration procedures for MEHO 002 with domestic and international organizations and are in the process of patent registration."

Tubulysin, the main ingredient of the anticancer drug M001 under development by Mekox Cure Med, is known to have up to 100 times stronger anticancer effects compared to existing anticancer substances. However, due to its very complex chemical structure, chemical synthesis and cultivation have been difficult, causing challenges in securing the substance. Mekox Cure Med’s research team is accelerating the development of a mass production process for Tubulysin through continuous joint research with the myxobacteria research team at Hoseo University, which holds the Korean Myxobacteria Bank.

Founded in 2006, Mekox Cure Med’s most representative pipeline is the mass extraction of the powerful anticancer substance Tubulysin and the development of a nano drug targeted delivery technology platform. AIbit expects that once the mass production process for Tubulysin is completed, it will be easier to add pipelines for solid cancer treatments M004 and M005, and that the sale of Tubulysin itself will also become possible.

This content was produced with the assistance of AI translation services.